Skip to main content
. 2020 Feb 11;111(3):924–931. doi: 10.1111/cas.14306

Figure 1.

Figure 1

Design of a phase I dose‐escalation study of propagermanium (PG) used as an antimetastatic drug for perioperative patients with primary breast cancer